• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis >Clinical significance of GSTM1 and GSTT1 polymorphisms in younger patients with acute myeloid leukemia of intermediate-risk cytogenetics.
【24h】

Clinical significance of GSTM1 and GSTT1 polymorphisms in younger patients with acute myeloid leukemia of intermediate-risk cytogenetics.

机译：GSTM1和GSTT1基因多态性在年轻的急性髓细胞性白血病中危细胞遗传学患者中的临床意义。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

We investigated the association between GSTM1 or GSTT1 polymorphisms and clinical outcomes in 133 younger patients with AML of intermediate-risk cytogenetics. Clinical outcomes were not significantly different among the GSTM1 polymorphism genotypes, whereas cumulative incidence of relapse (CIR) was significantly lower and event-free survival (EFS) was significantly higher in patients with the GSTT1-present genotype compared with those with the GSTT1-null genotype (CIR at 5 year, 28.9% vs. 44.6%, P=0.018; EFS at 5 year, 51.4% vs. 34.1%, P=0.029). Our results suggest that GSTT1 gene polymorphism has significant clinical implications in younger patients with AML of intermediate-risk cytogenetics.
机译：我们调查了133名年轻的中度风险细胞遗传学AML患者中GSTM1或GSTT1多态性与临床结局之间的关联。 GSTM1多态性基因型之间的临床结局无显着差异，而GSTT1存在基因型的患者与无GSTT1基因型的患者相比，其累积复发率（CIR）显着降低，无事件生存（EFS）显着更高基因型（5年CIR，28.9％vs.44.6％，P = 0.018; 5年EFS，51.4％vs.34.1％，P = 0.029）。我们的结果表明，GSTT1基因多态性对年轻的中度风险细胞遗传学AML患者具有重要的临床意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号